Drug reimbursement: Indicators of inappropriate resource allocation

AIMS: In many countries, governments and third parties find themselves paying for (reimbursing) unproven, inadequate products limiting their ability to invest in therapies with evidence of relevant patient benefit. We examined how three characteristics, level of therapeutic evidence, susceptibility...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Bégaud, Bernard, Bergman, Ulf, Eichler, Hans-Georg, Leufkens, Hubert G M, Meier, Peter J
Format: Artigo
Sprache:Inglês
Veröffentlicht: Blackwell Science Inc 2002
Schlagworte:
Short Reports
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC1874470/
https://ncbi.nlm.nih.gov/pubmed/12445033
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1046/j.1365-2125.2002.01690.x
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge